Fresenius Kabi Introduces IDACIO® (adalimumab-aacf) as its First Immunology Biosimilar in the United States

Fresenius Kabi, a global healthcare company specializing in medicines and technologies, has announced the availability of its first immunology biosimilar, IDACIO® (adalimumab-aacf), in the United States. IDACIO® is indicated for use in the treatment of chronic autoimmune diseases and is a biosimilar to Humira® (adalimumab). It is available in a self-administered prefilled syringe and pre-filled ..

  • format_list_bulleted BS
  • · 2023. 7. 4.
  • textsms

Biden Administration Imposes Penalties on 43 Drugs Due to Price Hikes

The Biden administration is set to impose inflation penalties on 43 Medicare Part B drugs in Q3 of 2023, following the imposition of fines on 27 drugs in March. The Inflation Reduction Act stipulates that pharmaceutical manufacturers must provide justifications for any price increases exceeding the inflation rate, with financial penalties imposed if deemed insufficient. The latest actions are ex..

  • format_list_bulleted BS
  • · 2023. 6. 10.
  • textsms